VERAXA Biotech AG. VRXA Archives

ThursdayAug 27, 2026 1:30 pm

VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also…

MondayAug 24, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps. VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies. The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel…

FridayAug 21, 2026 3:30 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the…

FridayAug 21, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites. The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute. VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb. The company reported more than 50 granted owned or exclusively licensed patents across 26 patent…

TuesdayAug 18, 2026 12:53 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology

VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused research organization Ardigen could strengthen the company’s oncology pipeline as artificial intelligence plays an increasingly important role in drug discovery. By combining Ardigen’s expertise in AI, computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform, the companies aim to use AI to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while improving target validation and reducing development risks. VERAXA’s “AND-gated” approach, which activates therapies only when two cancer-associated targets are present on the same cell, may be particularly well suited to AI-driven analysis…

FridayAug 07, 2026 1:04 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

WednesdayAug 05, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb. OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs. VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.…

WednesdayJul 29, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. Recent regulatory feedback from Germany's Paul-Ehrlich-Institute has provided additional clarity for development of the company's lead BiTAC(R)-TCE program. Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics…

WednesdayJul 29, 2026 9:00 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047. The company said its BiTAC platform is designed to improve the selectivity and…

ThursdayJul 23, 2026 9:30 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the…

Site Search

Company Search

Tag: VERAXA Biotech AG. VRXA